NASDAQ:AXDX - Accelerate Diagnostics Stock Price, Forecast & News

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics Inc (NASDAQ:AXDX) announced its quarterly earnings data on Thursday, November, 7th. The medical research company reported ($0.37) EPS for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.01. The medical research company had revenue of $2.27 million for the quarter, compared to the consensus estimate of $3.15 million. Accelerate Diagnostics had a negative return on equity of 249.46% and a negative net margin of 1,116.69%. View Accelerate Diagnostics' Earnings History.

Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Accelerate Diagnostics.

Accelerate Diagnostics issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, January, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $16-18 million, compared to the consensus revenue estimate of $27.93 million.

4 Wall Street analysts have issued 1 year target prices for Accelerate Diagnostics' shares. Their forecasts range from $16.00 to $20.00. On average, they expect Accelerate Diagnostics' share price to reach $18.33 in the next year. This suggests a possible upside of 11.0% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.

News coverage about AXDX stock has been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Accelerate Diagnostics.

Some companies that are related to Accelerate Diagnostics include Horiba (HRIBF), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Arrayit (ARYC), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), BIOLASE (BIOL), Alibaba Group (BABA), ABIOMED (ABMD), Gilead Sciences (GILD), AT&T (T) and Vuzix (VUZI).

Accelerate Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Credit Suisse AG (5.68%), Chicago Capital LLC (2.40%), ArrowMark Colorado Holdings LLC (2.04%), Cannell Peter B & Co. Inc. (2.00%), Griffin Asset Management Inc. (1.82%) and State Street Corp (1.10%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Credit Suisse AG, Stifel Financial Corp, Barclays PLC, Cannell Peter B & Co. Inc., Bank of America Corp DE, New York State Common Retirement Fund and SeaCrest Wealth Management LLC. View Insider Buying and Selling for Accelerate Diagnostics.

AXDX stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Griffin Asset Management Inc., UBS Group AG, ArrowMark Colorado Holdings LLC, Baird Financial Group Inc., California Public Employees Retirement System, State Street Corp and M&T Bank Corp. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXDX stock can currently be purchased for approximately $16.51.

Accelerate Diagnostics has a market capitalization of $902.27 million and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.View Additional Information About Accelerate Diagnostics.

The official website for Accelerate Diagnostics is http://acceleratediagnostics.com/.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]